Supreme Court Leaves FDA To Its Own Devices In Regulating Fraud Claims
This article was originally published in The Gray Sheet
Executive Summary
The Supreme Court's Feb. 21 decision in Buckman Co. v. Plaintiffs Legal Committee defends off-label use as a vital "corollary" to FDA's regulatory scheme, while also investing sole authority in the agency to determine whether premarket submissions are fraudulent.
You may also be interested in...
FDA’s Court Retort: Device PMA Approval Preempts State Common Law Claims
State tort claims of device design defect, labeling, strict liability, negligence and failure to warn are preempted by PMA approval, the Department of Justice argues in a May brief filed on behalf of FDA
FDA’s Court Retort: Device PMA Approval Preempts State Common Law Claims
State tort claims of device design defect, labeling, strict liability, negligence and failure to warn are preempted by PMA approval, the Department of Justice argues in a May brief filed on behalf of FDA
Medtronic Fraud Case Review Casts Doubt On FDA Tort Challenges – WLF
The Cincinnati appeals court's decision to review a lawsuit alleging that Medtronic made false claims to FDA portends a favorable decision for manufacturers, according to the Washington Legal Foundation